BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21860243)

  • 1. Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients.
    Matsumoto K; Miyake Y; Kato H; Kawamoto H; Imagawa A; Toyokawa T; Nakatsu M; Ando M; Hirohata M; Yamamoto K
    Digestion; 2011; 84(3):230-5. PubMed ID: 21860243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.
    Yamagishi Y; Higuchi H; Izumiya M; Sakai G; Iizuka H; Nakamura S; Adachi M; Hozawa S; Takaishi H; Hibi T
    J Gastroenterol; 2010 Nov; 45(11):1146-54. PubMed ID: 20549255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.
    Nakai Y; Isayama H; Kawabe T; Tsujino T; Yoshida H; Sasaki T; Tada M; Arizumi T; Yagioka H; Kogure H; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Omata M
    Pancreas; 2008 Nov; 37(4):405-10. PubMed ID: 18953253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.
    Kuriyama H; Kawana K; Taniguchi R; Jono F; Sakai E; Okubo H; Suzuki H; Kobayashi S; Murata Y; Inamori M; Hata Y; Nakajima A
    Hepatogastroenterology; 2011; 58(105):26-30. PubMed ID: 21510281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gemcitabine therapy for unresectable pancreatic cancer in elderly patients].
    Katakura Y; Nakahara K; Kobayashi M; Adachi S; Izawa N; Noguchi Y; Nakatsu S; Sato Y; Takagi R; Itoh F
    Nihon Shokakibyo Gakkai Zasshi; 2010 Mar; 107(3):396-406. PubMed ID: 20203443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
    Dalgleish AG; Stebbing J; Adamson DJ; Arif SS; Bidoli P; Chang D; Cheeseman S; Diaz-Beveridge R; Fernandez-Martos C; Glynne-Jones R; Granetto C; Massuti B; McAdam K; McDermott R; Martín AJ; Papamichael D; Pazo-Cid R; Vieitez JM; Zaniboni A; Carroll KJ; Wagle S; Gaya A; Mudan SS
    Br J Cancer; 2016 Sep; 115(7):789-96. PubMed ID: 27599039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
    Ma G; Sun Y; Fu S
    Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
    J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent gemcitabine in elderly patients with unresectable biliary tract cancer.
    Kuriyama H; Kawana K; Taniguchi R; Jono F; Sakai E; Ohubo H; Suzuki H; Kobayashi S; Murata Y; Inamori M; Hata Y; Nahajima A
    Hepatogastroenterology; 2011; 58(106):270-4. PubMed ID: 21661380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
    Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
    Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer.
    Shimoda M; Katoh M; Kita J; Sawada T; Kubota K
    Chemotherapy; 2010; 56(6):501-6. PubMed ID: 21099223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
    Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
    Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
    J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
    Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
    J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy.
    Takasawa O; Fujita N; Kobayashi G; Noda Y; Ito K; Horaguchi J
    World J Gastroenterol; 2006 Dec; 12(45):7299-303. PubMed ID: 17143944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
    Vogel A; Römmler-Zehrer J; Li JS; McGovern D; Romano A; Stahl M
    BMC Cancer; 2016 Oct; 16(1):817. PubMed ID: 27769210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients.
    Kuroda T; Kumagi T; Yokota T; Azemoto N; Hasebe A; Seike H; Nishiyama M; Inada N; Shibata N; Miyata H; Kawamura T; Imai Y; Ueno-Toshimori A; Tanaka Y; Terao T; Imamura Y; Koizumi M; Yamanishi H; Ohno Y; Hiasa Y;
    BMC Gastroenterol; 2017 May; 17(1):66. PubMed ID: 28532457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.